Q1 EPS Estimates for Daré Bioscience Decreased by Analyst

Daré Bioscience, Inc. (NASDAQ:DARE) – Equities researchers at Brookline Capital Management dropped their Q1 2025 earnings per share estimates for shares of Daré Bioscience in a research report issued to clients and investors on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now anticipates that the biotechnology company will post earnings per share of ($0.68) for the quarter, down from their previous estimate of ($0.54). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q2 2025 earnings at ($0.62) EPS and FY2025 earnings at ($2.48) EPS.

Daré Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02. The firm had revenue of ($0.06) million during the quarter, compared to the consensus estimate of $1.00 million.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday.

Daré Bioscience Trading Up 0.3 %

Daré Bioscience stock opened at $2.91 on Thursday. Daré Bioscience has a 1 year low of $2.67 and a 1 year high of $7.56. The company’s 50-day moving average is $3.04 and its two-hundred day moving average is $3.28. The company has a market cap of $25.32 million, a PE ratio of -4.93 and a beta of 1.38.

Hedge Funds Weigh In On Daré Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AMH Equity Ltd increased its stake in shares of Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 50,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Daré Bioscience by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 3,593 shares during the period. Renaissance Technologies LLC increased its stake in Daré Bioscience by 6.7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 4,300 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Daré Bioscience in the fourth quarter worth $52,000. Institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.